Evidence map›Paper›PMID 33212896›Full record

ArticleJournal of clinical medicine2020

Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1.

Kanagasabai Vadivel, Anne K Zaiss, Yogesh Kumar, Frank M Fabian, Ayman E A Ismail, Mark A Arbing, Wallace G Buchholz, William H Velander, S Paul Bajaj

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 67% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Kanagasabai VadivelDepartment of Orthopedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Anne K ZaissDepartment of Orthopedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Yogesh KumarDepartment of Orthopedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Frank M FabianDepartment of Chemical and Biomolecular Engineering, University of Nebraska, Lincoln, NE 68588, USA.
Ayman E A IsmailDepartment of Chemical and Biomolecular Engineering, University of Nebraska, Lincoln, NE 68588, USA.
Mark A ArbingProtein Expression Technology Center, UCLA-DOE Institute, University of California, Los Angeles, CA 90095, USA.
Wallace G BuchholzDepartment of Chemical and Biomolecular Engineering, University of Nebraska, Lincoln, NE 68588, USA.
William H VelanderDepartment of Chemical and Biomolecular Engineering, University of Nebraska, Lincoln, NE 68588, USA.
S Paul BajajDepartment of Orthopedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
University of California, Los Angeles · USUniversity of Nebraska–Lincoln · USProtein Express (United States) · USWalla Walla University · US

Funding

Molecular and Structural Recognition in Factor VIIa Induced CoagulationR01HL141850 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VADIVEL, KANAGASABAI · 2018 to 2021
$1.6M
NHLBI NIH HHS R01 HL141850NHLBI NIH HHS R01HL141850
6 · The paper itself

Abstract

Current antifibrinolytic agents reduce blood loss by inhibiting plasmin active sites (e.g., aprotinin) or by preventing plasminogen/tissue plasminogen activator (tPA) binding to fibrin clots (e.g., ε-aminocaproic acid and tranexamic acid); however, they have adverse side effects. Here, we expressed 60-residue (

Indexed as

antifibrinolyticsaprotininthromboelastographytranexamic acidε-aminocaproic acid

Identifiers

PMID33212896
PMCPMC7698382
OpenAlexW3101005196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.